In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

AAPS PharmSciTech

Volumn 6, Issue 3, 2005, Pages

  Malhotra, Manjusha ^a   Majumdar, Dipak K ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; EDETIC ACID; EYE DROPS; EYE OINTMENT; KETOROLAC; SESAME SEED OIL; SOYBEAN OIL;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MATHEMATICAL COMPUTING; NONHUMAN; QUANTITATIVE ANALYSIS; RABBIT;

EID: 27744432334     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060365     Document Type: Article

References (21)

1. Herch PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990-108:577.
2. Cooper CA, Bergamini MVW, Leopold IH, Use of flurbiprofen to inhibit corneal neovascularization. Arch Ophthalmol, 1980;98:1102-1105.
3. Kraff MC, Sanders DR, Mcguigan L, Rannan MG. Inhibition of blood- aqueous humor barrier breakdown with diclofenac: a fluorometric study. Arch Ophthalmol. 1990; 108:380-383.
4. Searle AE, Pearce JL, Shaw DE. Topical use of indomethacin on the day of cataract surgery. Br J Ophthalmol. 1990;74:19.
5. Mahoney JM, Waterbury LD. (±) 5 benzoyl-1,2-dihydro-3H pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS 37619]: a non irritating ophthalmic anti-inflammatory agent. Invest Ophthalmol Vis Sci. 1983;24:151-159.
6. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post surgical blood aqueous barrier. Arch Ophthalmol. 1988;106:480-483.
7. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate, to severe ocular inflammation after cataract surgery: a randomized vehicle - controlled clinical trial. Am J Ophthalmol. 1999;127:253-259.
8. Solomen KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331-337.
9. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Candida albicans ocular infection in rabbit. Arch Ophthamol. 1987;105:264-267.
10. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. J Ocul Pharmacol. 1988;4:101-109.
11. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudoaphakic cystoid macular edema. Am J Ophthalmol. 1987;103:479-486.
12. Price FW, Jr, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double -masked, placebo controlled trial. J Refract Surg. 2002;18:140-144.
13. Malhotra M, Majumdar DK. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine. Indian J Exp Biol. 2002;40:555-559.
14. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J Exp Biol. 1997;35:1324-1330.
15. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits. J Pharm Sci. 1987;76:289-294.
16. Madhu C, Rix PJ, Shackleton MJ, Nguyen TG, Tang-Liu DDS. Effect of benzalkonium chloride /EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillations to normal and deepithelialized corneas of rabbits. J Pharm Sci. 1996:85:415-418.
17. Pharmacopoeia of India. 2nd ed. Delhi, India: Government of India, Ministry of Health and Family Welfare; 1970:296.
18. Fu RC, Lidgate DM. In vitro rabbit corneal permeability study of ketorolac tromethamine. Drug Dev Ind Pharm. 1986;12:2403-2430.
19. Grass GM, Wood RW, Robinson JR. Effects of calcium chelating agents on corneal permeability. Invest Ophthalmol Vis Sci. 1985;26:11O
20. Kennah HE, Higney S, Laux PE, Dorko JD, Barrow CS. Fundam Appl Toxicol. 1989;12:258-268.
21. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability 1. Evaluation of fluorometholone. J Pharm Sci. 1975;64:931.